Status:
TERMINATED
Examination Of Vitiligo Skin Samples Before and After UVB Treatment
Lead Sponsor:
Mimi Cho, MD
Collaborating Sponsors:
American Skin Association
Conditions:
Vitiligo
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The keratinocytes of lesional skin of vitiligo compared to normal and perilesional skin will differentially express genes correlating with melanocyte death. Narrow Band UVB should then hopefully rever...
Detailed Description
Vitiligo is a disease caused by the disappearance of melanocytes in the epidermis. The pathogenesis of vitiligo is multifactorial. Theories include autoimmunity, neural, apoptosis and cytotoxicity. Th...
Eligibility Criteria
Inclusion
- Patients should have non-treated symmetrically active vitiligo for 3 months.
Exclusion
- Less than 18 years old and older that 65, pregnant women, segmental or nonactive vitiligo, patients treated for vitiligo in past 3 month, patients on topical steroid medications, topical tacrolimus or elidel, patients receiving ultraviolet therapy including narrow band UVB, PUVA or tanning beds.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00177034
Start Date
November 1 2004
End Date
December 1 2005
Last Update
July 10 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455